Classifying heart failure based on ejection fraction: imperfect but enduring

Affiliations

¹ Division of Cardiology, Duke University School of Medicine, Durham, NC, USA.
² Department of Medicine, Ziauddin Medical University, Karachi, Pakistan.
³ Division of Cardiology, University of California, Los Angeles, Los Angeles, CA, USA.
⁴ Duke Clinical Research Institute, Durham, NC, USA.

Free article

Muhammad Shahzeb Khan et al. Eur J Heart Fail. 2022 Jul.

Free article

. 2022 Jul;24(7):1154-1157.

doi: 10.1002/ejhf.2470. Epub 2022 Mar 20.

¹ Division of Cardiology, Duke University School of Medicine, Durham, NC, USA.
² Department of Medicine, Ziauddin Medical University, Karachi, Pakistan.
³ Division of Cardiology, University of California, Los Angeles, Los Angeles, CA, USA.
⁴ Duke Clinical Research Institute, Durham, NC, USA.

No abstract available

References

1. Greenberg B, O'Connor CM, Felker GM. Classifying heart failure in the 21st century: matching taxonomy with science. JACC Heart Fail. 2021;9:771-3.
1. Patel RB, Vaduganathan M, Greene SJ, Butler J. Nomenclature in heart failure: a call for objective, reproducible, and biologically-driven terminology. Eur J Heart Fail. 2018;20:1379-81.
1. Ferreira JP, Packer M, Butler J, Zannad F. Reconsidering the ejection fraction centric view of pharmacologic treatment for heart failure. Eur J Heart Fail. 2022.
1. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al.; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451-61.
1. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al.; PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609-20.